MEDP — what changed in the latest 10-Q
A section-by-section comparison of MEDP's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-07-23 vs the prior 10-Q · 2026-04-23
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +15 | −15 | ~19 | 19 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~1 | 4 |
| Legal proceedings | Text added/removed | 0 | 0 | ~1 | 1 |
| Other information | Text added/removed | +9 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Risk factors
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-07-23
The effect of foreign currency adjustments on backlog was as follows: favorable foreign currency adjustments of $0.1 million for the three months ended June 30, 2026; unfavorable foreign currency adjustments of $3.6 million for the six months ended June 30, 2026; favorable foreign currency adjustmen…
Six Months Ended June 30, 2026 compared to Six Months Ended June 30, 2025
Direct service costs, excluding depreciation and amortization400,829 363,642 37,187 10.2 %
Total revenue increased by $104.0 million, to $707.3 million for the three months ended June 30, 2026, from $603.3 million for the three months ended June 30, 2025. Total revenue increased by $252.1 million, to $1,413.9 million for the six months ended June 30, 2026, from $1,161.9 million for the si…
Total direct costs increased by $82.4 million, to $505.7 million for the three months ended June 30, 2026 from $423.3 million for the three months ended June 30, 2025. Total direct costs increased by $212.5 million, to $1,016.0 million for the six months ended June 30, 2026 from $803.5 million for t…
Text removed vs the prior filing · source: 10-Q · 2026-04-23
The effect of foreign currency adjustments on backlog was as follows: unfavorable foreign currency adjustments of $3.7 million for the three months ended March 31, 2026 and favorable foreign currency adjustments of $6.9 million for the three months ended March 31, 2025.
Total revenue increased by $148.0 million, to $706.6 million for the three months ended March 31, 2026, from $558.6 million for the three months ended March 31, 2025. The increase for the three months ended March 31, 2026 was primarily driven by growth within the Metabolic, Oncology, Central Nervous…
Total direct costs increased by $130.1 million, to $510.3 million for the three months ended March 31, 2026, from $380.2 million for the three months ended March 31, 2025. The increase was primarily attributed to higher reimbursed out-of-pocket expenses and higher personnel costs to support the grow…
Selling, general and administrative expenses decreased by $10.0 million, to $47.9 million for the three months ended March 31, 2026, from $57.9 million for the three months ended March 31, 2025. The decrease was primarily attributed to a decrease in stock-based compensation expense of $11.9 million,…
based compensation expense, to support the growth in service activities of $1.5 million for the three months ended March 31, 2026, compared to the same period in the prior year.
Other information
Text added vs the prior filing · source: 10-Q · 2026-07-23
ActionDateTrading ArrangementTotal Shares to be Purchased or SoldDuration/Expiration Date
The earlier of until cancelled or 180 days from the placement of the limit order
The earlier of until cancelled or 180 days from the placement of the limit order
The earlier of until cancelled or 180 days from the placement of the limit order
Intended to satisfy the affirmative defense of Rule 10b5-1(c).
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice